CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP

Journal of Psychopharmacology

Volumn 26, Issue 3, 2012, Pages 398-407

  Huezo Diaz, Patricia ^a   Perroud, Nader ^a   Spencer, Edgar P ^b   Smith, Rebecca ^a   Sim, Sarah ^c   Virding, Susanne ^c   Uher, Rudolf ^a,d   Gunasinghe, Cerisse ^a,d   Gray, Jo ^a,d   Campbell, Desmond ^a   Hauser, Joanna ^e   Maier, Wolfgang ^f   Marusic, Andrej ^g   Rietschel, Marcella ^h   Perez, Jorge ⁱ   Giovannini, Caterina ⁱ   Mors, Ole ^j   Mendlewicz, Julien ^k   McGuffin, Peter ^a,d   Farmer, Anne E ^a,d   Ingelman Sundberg, Magnus ^c   Craig, Ian W ^a   Aitchison, Katherine J ^a,d,l   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f UNIVERSITY OF BONN   (Germany)

^g NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

^h CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

ⁱ IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k ERASME HOSPITAL   (Belgium)

^l UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

Antidepressant agent; cytochrome P450 CYP2C19; cytochrome P450 CYP2D6; depressive disorder; escitalopram; pharmacogenetics

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; ESCITALOPRAM; N DESMETHYLESCITALOPRAM; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYP2C19 GENE; CYP2D6 GENE; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ENZYME ACTIVITY; FEMALE; GENE FUNCTION; GENE PRODUCT; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX RATIO; STEADY STATE; TREATMENT DURATION;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CITALOPRAM; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84863229220     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111414451     Document Type: Article

References (45)

1. Aitchison KJ, Jordan BD, Sharma T. The relevance of ethnic influences on pharmacogenetics to the treatment of psychosis. Drug Metabol Drug Interact. 2000 ; 16: 15-38 (Pubitemid 30090295)
2. Diagnostic and Statistical Manual of Mental Disorders (DSM IV). 1994) Diagnostic and Statistical Manual of Mental Disorders (DSM IV), 4th ed.Washington DC: American Psychiatric Association. Washington DC: American Psychiatric Association ; 1994 :
3. Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol. 1995 ; 10 (Suppl 1). 15-21
4. Bies RR, Feng Y, Lotrich FE, et al. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol. 2004 ; 44: 1352-1359 (Pubitemid 39518640)
5. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002 ; 63: 331-336 (Pubitemid 34456361)
6. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?. Anesthesiology. 2005 ; 102: 543-549 (Pubitemid 40315143)
7. Chen F, Larsen MB, Sanchez C, et al. The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005 ; 15: 193-198 (Pubitemid 40193425)
8. de Leon J. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn. 2006 ; 6: 277-286 (Pubitemid 44174334)
9. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994 ; 269: 15419-15422
10. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002 ; 41: 913-958 (Pubitemid 35168437)
11. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006 ; 57: 119-137 (Pubitemid 43261982)
12. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol. 2004 ; 19: 305-310 (Pubitemid 39141947)
13. Fredericson Overo K, Toft B, Christophersen L, et al. Kinetics of citalopram in elderly patients. Psychopharmacology (Berl). 1985 ; 86: 253-257 (Pubitemid 15064946)
14. Freeman B, Smith N, Curtis C, et al. DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping. Behav Genet. 2003 ; 33: 67-72 (Pubitemid 36176783)
15. Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002 ; 72: 453-460 (Pubitemid 35178870)
16. GaudermanW.MorrisonJ., Quanto 1.1: A computer program for power and sample size calculations for genetic-epigemiology studies. 2006. Retrieved from: http://hydra.usc.edu/gxe. (accessed January 2009).
17. Grayson D, Bridges K, Cook D, et al. The validity of diagnostic systems for common mental disorders: a comparison between the ID-CATEGO and the DSM-III systems. Psychol Med. 1990 ; 20: 209-218 (Pubitemid 20089631)
18. Gutierrez MM, Abramowitz W. Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: a single-dose, randomized, crossover study. Clin Ther. 2000 ; 22: 1525-1532 (Pubitemid 32056090)
19. Heller T, Kirchheiner J, Armstrong VW, et al. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit. 2006 ; 28: 673-677 (Pubitemid 44564068)
20. Herrlin K, Yasui-Furukori N, Tybring G, et al. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol. 2003 ; 56: 415-421 (Pubitemid 37188136)
21. Keers R, Ingelman-Sundberg MT, Hauser J, et al. CYP2D6 genotype predicts antidepressant dose in the GENDEP project. Eur Neuropsychopharmacol. 2010 ; 20 (Suppl 3). S172
22. Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokinet. 1997 ; 33: 302-312 (Pubitemid 27429896)
23. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004 ; 9: 442-473 (Pubitemid 38903502)
24. Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, et al. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol. 2006 ; 62: 877-880 (Pubitemid 44521437)
25. Llorca PM, Azorin JM, Despiegel N, et al. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract. 2005 ; 59: 268-275 (Pubitemid 40352741)
26. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol. 2005 ; 20: 131-137 (Pubitemid 40571510)
27. Ohlsson Rosenborg S, Mwinyi J, Andersson M, et al. Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol 64. 2008 ; 12: 1175-1179
28. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001 ; 50: 345-350 (Pubitemid 32816947)
29. PalovaaraTybring GLaineK (2003) The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol56: 232-237. (Pubitemid 36981441)
30. Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit. 2003 ; 25: 183-191 (Pubitemid 36373425)
31. Rudberg I, Mohebi B, Hermann M, et al. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2008 ; 83: 322-327
32. Sanchez C, Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav. 2004 ; 77: 391-398 (Pubitemid 38125173)
33. Sidhu J, Priskorn M, Poulsen M, et al. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality. 1997 ; 9: 686-692 (Pubitemid 27479378)
34. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006 ; 79: 103-113 (Pubitemid 43069582)
35. Sindrup SH, Brosen K, Hansen MG, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit. 1993 ; 15: 11-17 (Pubitemid 23040309)
36. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 ; 340: 249-258 (Pubitemid 28022649)
37. Taylor D, Kerwin R, Paton C The Maudsley 2005-2006 Prescribing Guidelines. 2006 ) The Maudsley 2005-2006 Prescribing Guidelines, 8th ed.Taylor & Francis, London. Taylor & Francis, London: ; 2006 :
38. Trzepacz PT, Williams DW, Feldman PD, et al. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol. 2008 ; 18: 79-86 (Pubitemid 350296843)
39. Uher R, Farmer A, Maier W, et al. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med. 2008 ; 38: 289-300 (Pubitemid 351156595)
40. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001 ; 29: 1102-1109 (Pubitemid 32660528)
41. Wang G, Lei HP, Li Z, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009 ; 65: 281-285
42. The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research. Geneva: ; 1993 :
43. Diagnosis and clinical measurements in psychiatry. A reference manual for SCAN. Geneva: World Health Organization ; 1998 :
44. Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther. 1997 ; 281: 604-609 (Pubitemid 27203121)
45. Yin OQ, Wing YK, Cheung Y, et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol. 2006 ; 26: 367-372 (Pubitemid 44192092)